Skip to content
Quest Laboratories logo

Quest Laboratories

QUESTLAB NSE
₹87.50

Close ·

P/E
9.55
View as Markdown
MCP
Close 3 Nov 2026 ₹87.50 +1.45 +1.69% 1Y
Start ₹86.05

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
18.30%
Debt to Equity
0.08
EPS (TTM)
₹9.16
Book Value
₹59.08
Market Cap
—
P/E (TTM)
9.55
P/B
1.48
ROE
16.60%
Dividend Yield
0.00%
EBITDA
₹20.60 Cr
52W High
₹152.60
52W Low
₹68.60

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

55 Good

Data confidence 100/100

Category scores

Quality
67
Strong
Returns, margins, earnings quality 22% weight
Valuation
58
Good
Cheap vs sector & own history 24% weight
Growth
49
Average
Sales & profit trajectory 9% weight
Financial Health
82
Strong
Solvency, leverage, coverage 9% weight
Momentum
21
Poor
Trend strength, vol-adjusted 12% weight
Ownership
48
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

4
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 86.4% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 23.2%

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Working capital days have increased from 116 days to 218 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish874
OscillatorsBearish270
Moving AveragesStrong Bearish604

Key readings

RSI (14)
49.77
Neutral
MACD (12,26,9)
−1.06
Bearish
SMA (50)
86.73
Bullish
SMA (200)
102.06
Bearish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
5Y+30.14%
3Y+21.79%
1Y+7.69%

Net profit

Net profit growth by window
5Y+71.88%
3Y+44.22%
1Y+7.14%

Operating cash flow

Operating cash flow growth by window
5YTurned negative
3YTurned negative
1YOutflow narrowed by ₹12 Cr

Operating margin· change in pp

Operating margin growth by window
5Y+12.74 pp
3Y+3.17 pp
1Y+0.69 pp

Trailing twelve months: The last four quarters end with the latest fiscal year, which the 1Y column covers.

Revenue by year

Revenue by year, ₹ crore
Mar 2021₹30.00 Cr
Mar 2022₹59.00 Cr
Mar 2023₹62.00 Cr
Mar 2024₹83.00 Cr
Mar 2025₹104 Cr
Mar 2026₹112 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2021₹1.00 Cr
Mar 2022₹4.00 Cr
Mar 2023₹5.00 Cr
Mar 2024₹10.00 Cr
Mar 2025₹14.00 Cr
Mar 2026₹15.00 Cr

Quarterly Results

₹ Cr

Results for the period ended Jun 2026 were due by 14 Aug 2026 and are not in this table yet.

QUESTLAB quarterly results, ₹ crore
Particulars Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
15.25
27.37
14.84
46.45
23.18
25.62
30.61
32.4
Expenses
13.47
18.56
14.18
45.64
19.36
22.24
23.7
28.26
Operating Profit
1.78
8.81
0.66
0.81
3.82
3.38
6.91
4.14
OPM %
11.67%
32.19%
4.45%
1.74%
16.48%
13.19%
22.57%
12.78%
Other Income
0.16
0.68
0.3
3.41
1.85
1.42
0.57
−1.31
Interest
0.13
0.37
0.04
0.37
0.64
0.58
0.47
0.16
Depreciation
0.15
0.14
0.15
0.19
0.21
0.21
0.2
0.21
PBT
1.66
8.98
0.77
3.66
4.82
4.01
6.81
2.46
Tax %
11.45%
32.41%
0%
47.27%
14.94%
0%
40.82%
−16.67%
Net Profit
1.48
6.06
0.78
1.94
4.1
4.02
4.03
2.87
EPS (₹)
0.9
3.7
0.48
1.18
2.5
2.45
2.46
1.75

Profit & Loss

₹ Cr
QUESTLAB profit and loss, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
30
59
62
83
104
112
Expenses
29
53
54
67
88
94
Operating Profit
1
6
8
16
16
18
OPM %
4.7%
11%
13%
19%
15%
16%
Other Income
0
0
0
0
4
2
Interest
0
0
1
1
1
2
Depreciation
0
0
1
1
1
1
PBT
1
6
7
14
19
18
Tax %
18%
29%
28%
30%
27%
17%
Net Profit
1
4
5
10
14
15
EPS (₹)
—
—
—
8.45
8.37
9.07
Div. Payout %
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
QUESTLAB balance sheet, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1
1
1
12
16
16
Reserves
5
9
14
17
66
80
Borrowings
3
3
4
5
30
8
Other Liabilities
9
22
28
27
10
7
Total Liabilities
18
35
47
61
122
112
Fixed Assets
6
7
10
10
12
15
CWIP
0
0
0
0
0
1
Investments
0
0
0
7
52
16
Other Assets
12
27
37
44
58
80
Total Assets
18
35
47
61
122
112

Cash Flow

₹ Cr
QUESTLAB cash flow, annual, ₹ crore
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1
3
4
3
−23
−11
Investing
−1
−2
−4
−5
−44
35
Financing
0
0
0
2
67
−24
Net Cash Flow
0
1
0
0
0
0
Free Cash Flow
0
2
1
2
−23
−16
CFO/EBITDA
103
57
72
46
−120
−33

Ratios

QUESTLAB financial ratios, annual
Particulars Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
110
135
118
108
105
118
Inventory Days
12
9
97
113
99
163
Days Payable
119
140
215
144
26
24
Cash Conversion Cycle
3
4
1
77
178
258
Working Capital Days
9
14
27
58
72
218
ROCE %
—
55%
47%
57%
27%
18%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Quest Laboratories insights

59 extracted metrics across FY21–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 66.78%
  • Public 27.77%
  • Others 2.89%
  • DIIs 1.90%
  • FIIs 0.66%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

  • Concall · Jul 2025
    PPT
  • Concall · Jun 2025
    PPT
  • Concall · Dec 2024
    PPT

Frequently Asked Questions about Quest Laboratories

What does Quest Laboratories Ltd do?
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments
Where is Quest Laboratories Ltd (QUESTLAB) listed?
Quest Laboratories Ltd trades as QUESTLAB on the NSE.
Which sector does Quest Laboratories Ltd belong to?
Quest Laboratories Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Quest Laboratories Ltd?
Quest Laboratories Ltd trades at a PE ratio of 9.55 as of 3 Nov 2026, on earnings per share of ₹9.16, against a book value of ₹59.08 per share.
What is the 52-week high and low of Quest Laboratories Ltd?
Over the last 52 weeks Quest Laboratories Ltd has traded between ₹68.6 and ₹152.6 as of 3 Nov 2026.
What is the Return on Equity (ROE) of Quest Laboratories Ltd?
Quest Laboratories Ltd reported a return on equity of 16.60%. Its debt-to-equity ratio is 0.08.

Company Information

Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments

Website questlabltd.com
Listed 23 May 2024
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/QUESTLAB.md for Quest Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month